India First Strategy Could Speed Up Data For FDA-EU Approvals - Mumbai Conference
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Pharmaceutical companies may be able to take advantage of the relative speed to market in India to commercialize products earlier and obtain postmarketing data that could bolster drug approval applications filed later in the U.S. and Europe, according to Biocon Founder and Chairman Kiran Mazumdar-Shaw
You may also be interested in...
Dr. Reddy's Makes Headway With Internally Developed Phase III Diabetes Compound
Type 2 diabetes compound balaglitozone could be the first innovative Indian product to reach the market.
Dr. Reddy's Makes Headway With Internally Developed Phase III Diabetes Compound
Type 2 diabetes compound balaglitozone could be the first innovative Indian product to reach the market.
Biocon Partners With Biotech Startup In Latest India-U.S. Deal
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
Need a specific report? 1000+ reports available
Buy Reports